{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:05:11Z","timestamp":1783764311619,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> Cancer is a neoplastic transformation that affects tissue. Among the many complications associated with cancer treatment, managing the distressing side effects of chemotherapy-induced nausea and vomiting (CINV) is of main concern. Ondansetron is a selective serotonin 5-HT3 receptor antagonist that has emerged as an essential medication against CINV in adult cancer patients. Ondansetron efficacy and tolerability have made it a primary medication in CINV prophylaxis and treatment regimens. The study aims to offer a detailed overview of ondansetron\u2019s effectiveness, safety, and impact on patients\u2019 lives, ultimately contributing to the ongoing research to enhance the quality of cancer care.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> On 4 September 2023, a search was conducted of the <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> database using the search terms \u201ccancer,\u201d \u201condansetron,\u201d and \u201cZofran.\u201d Inclusion and exclusion criteria were defined to select relevant clinical trials. Included trials were completed with results and interventional studies that assessed the preventive effects of ondansetron on CINV in adult cancer patients.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 23 clinical trials were identified, with only 13 of them focusing on investigating the preventive effects of ondansetron on CINV in adult cancer patients. The collective findings from these trials showed an effective management of CINV using ondansetron.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Through a comprehensive overview of clinical trials, the use of ondansetron in adult cancer patients represents a significant improvement in CINV management.<\/jats:p>","DOI":"10.3389\/fphar.2023.1310455","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T04:56:59Z","timestamp":1700715419000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The preventive effects of ondansetron on chemotherapy-induced nausea and vomiting in adult cancer patients: systematic review from ClinicalTrials.gov"],"prefix":"10.3389","volume":"14","author":[{"given":"Ahmed M.","family":"Ashour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1291235","DOI":"10.3389\/fphar.2023.1291235","article-title":"Efficacy and safety of ondansetron for morning sickness in pregnancy: a systematic review of clinical trials","volume":"14","author":"Ashour","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B2","article-title":"Ondansetron","volume-title":"StatPearls","author":"Griddine","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0936-6555(05)80686-7","article-title":"The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children","volume":"5","author":"Hewitt","year":"1993","journal-title":"Clin. Oncol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/B978-0-12-387817-5.00040-6","article-title":"LiverTox: a website on drug-induced liver injury","volume-title":"Drug-induced liver disease","author":"Hoofnagle","year":"2013"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s40265-016-0663-3","article-title":"Comparative pharmacology and guide to the use of the serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting","volume":"76","author":"Kovac","year":"2016","journal-title":"Drugs"},{"key":"B6","unstructured":"Ondansetron in preventing nausea and vomiting in patients undergoing stem cell transplant"},{"key":"B7","unstructured":"Palonosetron versus ondansetron for the prevention of nausea and vomiting"},{"key":"B8","unstructured":"Aprepitant in preventing nausea and vomiting in patients who are undergoing a stem cell transplant"},{"key":"B9","unstructured":"A study of IV casopitant for the prevention of chemotherapy induced nausea and vomiting"},{"key":"B10","unstructured":"Ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis after receiving cisplatin2010"},{"key":"B11","unstructured":"Ondansetron versus palonosetron antiemetic regimen prior to highly emetogenic chemotherapy(HEC)"},{"key":"B12","unstructured":"Aprepitant's effect on drug metabolism in multi-day combination (CHOP\/\u200bR-CHOP) chemotherapy regimen in lymphoma patients"},{"key":"B13","unstructured":"Aprepitant versus ondansetron in preoperative triple-therapy treatment of nausea and vomiting2013"},{"key":"B14","unstructured":"A Korean study of efficacy and safety of aprepitant-based triple regimen for the prevention of chemotherapy-induced nausea and vomiting in the first cycle of moderately emetogenic chemotherapy (Non-doxorubicin hydrochloride [adriamycin] and cyclophosphami2014"},{"key":"B15","unstructured":"Antiemetic therapy with or without olanzapine in preventing chemotherapy-induced nausea and vomiting in patients with cancer receiving highly emetogenic chemotherapy2015"},{"key":"B16","unstructured":"Dexamethasone and ondansetron hydrochloride or palonosetron hydrochloride in preventing nausea and vomiting in patients receiving doxorubicin hydrochloride and cyclophosphamide for early stage breast cancer"},{"key":"B17","unstructured":"Emend and ondansetron compared to ondansetron alone to prevent CINV in glioma patients receiving temozolomide"},{"key":"B18","unstructured":"Oral ondansetron versus transdermal granisetron (sancuso) for women with cervical, endometrial or vaginal cancer receiving pelvic chemoradiation2019"},{"key":"B19","first-page":"232","article-title":"Chemotherapy-induced nausea and vomiting: optimizing prevention and management","volume":"5","author":"Rao","year":"2012","journal-title":"Am. Health and Drug Benefits"},{"key":"B20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"B22","first-page":"47","article-title":"Safety of ondansetron","volume":"25","author":"Smith","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B24","article-title":"Nausea and vomiting related to cancer treatment (PDQ\u00ae)","volume-title":"PDQ cancer information summaries","author":"Supportive","year":"2023"},{"key":"B25","volume-title":"Antiemetic serotonin-5-HT3 receptor blockers","author":"Theriot","year":"2018"},{"key":"B26","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/anae.15295","article-title":"Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: an abridged Cochrane network meta-analysis","volume":"76","author":"Weibel","year":"2021","journal-title":"Anaesthesia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3458.2001.tb00195.x","article-title":"Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders","volume":"7","author":"Ye","year":"2001","journal-title":"CNS Drug Rev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1310455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T04:57:07Z","timestamp":1700715427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1310455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":27,"alternative-id":["10.3389\/fphar.2023.1310455"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1310455","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"article-number":"1310455"}}